Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The epitope recognized by rituximab.

Mascha Binder1, Florian Otto, Roland Mertelsmann

  • 1Department of Hematology and Oncology, University of Freiburg Medical Center, Hugstetter Strasse 55, D-79106 Freiburg, Germany.

Blood
|May 18, 2006
PubMed
Summary

Rituximab targets CD20, but its exact binding site was unknown. Researchers identified a discontinuous epitope on CD20, comprising two peptide sequences, ANPS and YCYSI, crucial for rituximab binding.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward precision immunotherapy in recurrent/metastatic head and neck squamous cell carcinoma: lessons from the FOCUS trial.

Translational cancer research·2026
Same author

MPXV H3L elicits broadly directed CD4 T cell responses in mpox patients and MVA vaccinees.

Npj viruses·2026
Same author

OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer.

Communications medicine·2026
Same author

Cytotoxic CD39<sup>+</sup> tumor-associated NK cells respond to NKG2A blockade in lung cancer.

Science immunology·2026
Same author

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group.

British journal of cancer·2026
Same author

Primary mediastinal B-cell lymphoma: upfront high-dose chemotherapy with autologous stem cell transplantation results in favorable long-term outcome and may spare radiotherapy.

Annals of hematology·2026

Area of Science:

  • Immunology
  • Molecular Biology
  • Biochemistry

Background:

  • Rituximab is a key monoclonal antibody for treating lymphoma and autoimmune diseases.
  • The precise epitope recognized by rituximab on the CD20 antigen remains largely uncharacterized.

Purpose of the Study:

  • To identify the specific epitope on CD20 recognized by rituximab.
  • To elucidate the structural basis of rituximab-CD20 interaction.

Main Methods:

  • Phage display libraries were employed to select peptides that bind to rituximab.
  • Binding affinities and blocking assays using recombinant CD20 proteins and mutated peptides were performed.

Main Results:

  • Two peptide motifs, CALMIANSC and WEWTI, were identified, mimicking CD20 sequences (170)ANPS(173) and (182)YCYSI(185) respectively.

Related Experiment Videos

  • Binding was enhanced when both CD20 peptide sequences were linked, and recombinant CD20 proteins blocked phage binding.
  • Mutations in the ANPS or YCYSI sequences significantly reduced rituximab binding capacity.

    • Conclusions:

    • Rituximab binds to a discontinuous epitope on CD20.
    • This epitope is composed of the (170)ANPS(173) and (182)YCYSI(185) regions of CD20.
    • A disulfide bridge between C(167) and C(183) likely brings these two regions into steric proximity for rituximab binding.